Recent research have centered on the convergence of GLP-1|GIP|glucagon receptor agonist therapies and DA signaling. While GIP activators are commonly employed for treating type 2 T2DM, their potential effects on motivation circuits, specifically governed by DA systems, are attracting considerable focus. This paper provides a brief assessment of … Read More